[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334482-105":59,"doc-detail-334482-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","peritumoral-administration-of-immunomodulatory-antibodies-as-a-triple-combination-suppresses-skin-tumor-growth-without-systemic-toxicity","Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity","","Skin cancers, especially keratinocyte cancers, are among the most frequent tumors, and while early surgery can help, lesions may be hard to access, recur, and metastasize. This study tested whether peritumoral delivery of a PD-1/4-1BB (CD137)/VISTA antibody combination can control skin tumors, generate circulating antitumor immunity, and avoid off-target toxicity. Efficacy was evaluated in mouse tumor models with flow cytometry and ELISPOT, while safety used liver-focused histology and serum alanine aminotransferase ELISA.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/peritumoral-administration-of-immunomodulatory-antibodies-as-a-triple-combination-suppresses-skin-tumor-growth-without-systemic-toxicity/334482/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/peritumoral-administration-of-immunomodulatory-antibodies-as-a-triple-combination-suppresses-skin-tumor-growth-without-systemic-toxicity/334482.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What therapeutic strategy does the study evaluate for skin cancer?","Question",{"text":113,"@type":114},"It evaluates peritumoral administration of a triple antibody combination targeting PD-1, 4-1BB (CD137), and VISTA.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was treatment efficacy and tumor-immune response measured?",{"text":118,"@type":114},"Efficacy was assessed using transplantable tumor models in mouse ears or flank skin, with tumor microenvironment changes tracked by flow cytometry and tumor-specific CD8 T cells measured by ELISPOT.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence shows the approach avoids off-target toxicity?",{"text":122,"@type":114},"The combination eliminated tumors without measured hepatic toxicity, assessed using serum alanine aminotransferase ELISA and histological analysis of liver sections.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},334482,1790013178,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Open access  \nTo cite: Wright QG,  \nSinha D, Wells JW, et al. Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity. Journal for ImmunoTherapy of Cancer 2024;12:e007960 . doi:10.1136/jitc-2023-007960  \n► Additional supplemental material is published online only. To view, please visit the journal online ([http://dx.doi.org/10](http://dx.doi.org/10) . 1136/jitc-2023-007960) .  \nIHF and JLGC contributed equally.  \nAccepted 11 January 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFrazer Institute, The University of Queensland, Brisbane, Queensland, Australia  \nCorrespondence to  \nDr Graham Robert Leggatt; [g.leggatt@uq.edu.au](g.leggatt@uq.edu.au)  \nOriginal research  \nPeritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity  \nQuentin G Wright  , Debottam Sinha  , James W Wells  , Ian H Frazer, Jazmina L Gonzalez Cruz  , Graham Robert Leggatt   \nABSTRACT  \nBackground Skin cancers, particularly keratinocyte cancers, are the most commonly diagnosed tumors. Although surgery is often effective in early-stage disease, skin tumors are not always easily accessible, can reoccur and have the ability to metastasize. More recently, immunotherapies, including intravenously administered checkpoint inhibitors, have been shown to control some skin cancers, but with off-target toxicities when used in combination. Our study investigated whether peritumoral administration of an antibody combination targeting PD-1, 4-1BB (CD137) and VISTA might control skin tumors and lead to circulating antitumor immunity without off-target toxicity.  \nMethods The efficacy of combination immunotherapy administered peritumorally or intravenously was  \ntested using transplantable tumor models injected into mouse ears (primary tumors) or subcutaneously in flank skin (secondary tumors) . Changes to the tumor microenvironment were tracked using flow cytometry while tumor-specific, CD8 T cells were identified through enzyme-linked immunospot (ELISPOT) assays. Off-target toxicity of the combination immunotherapy was assessed via serum alanine aminotransferase ELISA and histological analysis of liver sections.  \nResults The data showed that local administration of antibody therapy eliminated syngeneic murine tumors transplanted in the ear skin at a lower dose than required intravenously, and without measured hepatic toxicity. Tumor elimination was dependent on CD8 T cells and was associated with an increased percentage of CD8 T cells expressing granzyme B, KLRG1 and Eomes, and a decreased population of CD4 T cells including CD4+FoxP3+ cells in the treated tumor microenvironment. Importantly, untreated, distal tumors regressed following antibody treatment of a primary tumor, and immune memory prevented growth of subcutaneous flank tumors administered 50 days after regression of a primary tumor. Conclusions Together, these data suggest that peritumoral immunotherapy for skin tumors offers advantages over conventional intravenous delivery, allowing antibody dose sparing, improved safety and inducing long-term systemic memory. Future clinical trials of immunotherapy for primary skin cancer should focus on peritumoral delivery of combinations of immune checkpoint antibodies.  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Intravenously administered antibodies against checkpoint molecules such as PD-1 and CTLA-4 are being used in the clinic to treat skin cancers. However, a subset of tumors can be resistant to this therapy and off target toxicities can be problematic particularly when combinations of antibodies are used. There is a clear clinical need for optimizing new combinations of checkpoint antibodies with improved efficacy that can be delivered in a safe manner for the treatment of skin cancer.\u003Cbr>WHAT THIS STUD","cbCairXNULxbIqjp","https://ap.wps.com/l/cbCairXNULxbIqjp","pdf",3454732,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Background","[{\"question\":\"What therapeutic strategy does the study evaluate for skin cancer?\",\"answer\":\"It evaluates peritumoral administration of a triple antibody combination targeting PD-1, 4-1BB (CD137), and VISTA.\"},{\"question\":\"How was treatment efficacy and tumor-immune response measured?\",\"answer\":\"Efficacy was assessed using transplantable tumor models in mouse ears or flank skin, with tumor microenvironment changes tracked by flow cytometry and tumor-specific CD8 T cells measured by ELISPOT.\"},{\"question\":\"What evidence shows the approach avoids off-target toxicity?\",\"answer\":\"The combination eliminated tumors without measured hepatic toxicity, assessed using serum alanine aminotransferase ELISA and histological analysis of liver sections.\"}]","Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity | PDF",1790006821]